Molecular Classification, Antimicrobial Mechanisms, and Mucosal Immune Regulation of the Defensin Family
Molecular Classification, Antimicrobial Mechanisms, and Mucosal Immune Regulation of the Defensin Family
Defensins are cysteine-rich cationic antimicrobial peptides produced primarily by neutrophils, intestinal Paneth cells, and various mucosal epithelial cells. They can directly disrupt microbial membranes, entrap pathogens, recruit immune cells, and regulate the mucosal microbiota, making them important effector molecules of the innate immune barrier.
Keywords: defensins; α-defensins; β-defensins; HNP; HD5; HD6; antimicrobial peptides; mucosal immunity
1 Molecular Basis of the Defensin Family
1.1 Basic Characteristics of Defensins
Mature defensins generally consist of approximately 29–45 amino acids and contain six conserved cysteine residues that form three intramolecular disulfide bonds. These disulfide bonds stabilize the short peptides in a β-sheet conformation, allowing them to maintain their structure in protease-rich environments such as neutrophil granules, the intestinal lumen, and mucosal secretions. Most defensins carry a net positive charge and can recognize negatively charged bacterial membranes, fungal membranes, or viral envelopes through electrostatic interactions.
1.2 α-Defensins and β-Defensins
Human defensins are primarily classified into α-defensins and β-defensins. The two groups share similar three-dimensional scaffolds but differ mainly in cysteine spacing, disulfide-bond connectivity, tissue origin, and maturation processes.The disulfide bonds of α-defensins generally connect Cys1–Cys6, Cys2–Cys4, and Cys3–Cys5. This group includes the neutrophil-derived HNP-1–4 and the Paneth cell-derived HD5 and HD6. The disulfide bonds of β-defensins generally connect Cys1–Cys5, Cys2–Cys4, and Cys3–Cys6. β-Defensins are produced mainly by epithelial cells in the skin, respiratory tract, gastrointestinal tract, and urogenital tract.
Table 1. Major classes of human defensins
Category | Representative Members | Major Sources | Functional Characteristics |
Neutrophil α-defensins | HNP-1, HNP-2, HNP-3, HNP-4 | Neutrophil azurophilic granules | Intracellular killing, extracellular antimicrobial activity, and inflammatory regulation |
Intestinal α-defensins | HD5, HD6 | Small-intestinal Paneth cells | Protection of intestinal crypts and restriction of pathogen colonization |
Classical β-defensins | HBD-1, HBD-2, HBD-3, HBD-4 | Skin and multiple mucosal epithelia | Epithelial defense, antimicrobial activity, and immune-cell recruitment |
Tissue-selective β-defensins | HBD-5, DEFB118, and related members | Reproductive tract and other specific tissues | Local antimicrobial activity and tissue-barrier protection |
1.3 Precursor Synthesis and Maturation of Defensins
Defensins are generally synthesized as precursor proteins containing a signal peptide, a propeptide region, and a mature peptide region. The signal peptide directs the peptide into the secretory pathway, whereas the propeptide region neutralizes the positive charge of the mature peptide and prevents defensins from inappropriately attacking host-cell membranes.Neutrophil α-defensins are processed during granule formation. Intestinal α-defensins require tissue-specific proteases for maturation. Trypsin participates in HD5 processing in the human intestine, whereas the maturation of mouse Paneth cell α-defensins mainly depends on MMP7.
2 Major Members of the α-Defensin Family
2.1 HNP-1, HNP-2, and HNP-3
HNP-1, HNP-2, and HNP-3 are highly abundant α-defensins in human neutrophils. Their sequences are highly similar, with the principal differences occurring at the N-terminus. HNP-2 can also be generated through N-terminal processing of HNP-1 or HNP-3.
After neutrophils engulf pathogens, HNP-containing azurophilic granules fuse with phagosomes. Neutrophil degranulation, neutrophil extracellular trap formation, and cellular injury can also release HNPs into the extracellular environment.
2.2 HNP-4
HNP-4 differs substantially in sequence from HNP-1–3 and is present at relatively low levels in neutrophils. Nevertheless, it exhibits strong activity against certain Gram-negative bacteria.
Individual HNP members differ in membrane-binding capacity, salt sensitivity, and antimicrobial spectrum. Total HNP levels reflect the overall release of neutrophil α-defensins but cannot replace the quantitative and functional analysis of individual members.
2.3 HD5 and the Intestinal Antimicrobial Barrier
Human defensin 5 (HD5) is produced mainly by small-intestinal Paneth cells and stored in secretory granules. Bacterial components, cholinergic stimulation, and tissue injury can promote its release.Mature HD5 can bind bacterial membranes and alter membrane permeability. It directly inhibits various bacteria and some fungi and can also restrict microbial access to the intestinal crypt stem-cell compartment.
2.4 HD6 and Pathogen Entrapment
Human defensin 6 (HD6) has relatively limited direct membrane-disrupting activity. Its principal characteristic is the ability to self-assemble into fibrous nanonets on pathogen surfaces.These nanonets can envelop bacteria and prevent their adhesion to or invasion of epithelial cells. The entrapped pathogens can subsequently be cleared through intestinal peristalsis and mucus renewal.
3 Major Members of the β-Defensin Family
3.1 HBD-1: Constitutive Epithelial Defense
Human β-defensin 1 (HBD-1), encoded by the DEFB1 gene, is constitutively expressed at relatively stable levels in epithelial tissues of the kidneys, respiratory tract, gastrointestinal tract, and urogenital tract.The activity of HBD-1 is influenced by the redox environment. Reduction of its disulfide bonds changes its conformation and exposes hydrophobic regions, potentially producing stronger activity against certain anaerobic bacteria.
3.2 HBD-2: An Inflammation-Inducible Defensin
Human β-defensin 2 (HBD-2) has low basal expression in most tissues. Bacterial products, IL-1β, TNF-α, and other inflammatory signals can induce its expression through pathways such as NF-κB and MAPK.In addition to directly inhibiting microorganisms, HBD-2 can recruit CCR6-positive immature dendritic cells and memory T cells, connecting innate epithelial defense with adaptive immune responses.
3.3 HBD-3: Broad-Spectrum Antimicrobial and Immunoregulatory Activity
Human β-defensin 3 (HBD-3) has a high net positive charge and is active against various Gram-positive bacteria, Gram-negative bacteria, and some fungi. It can retain a degree of antimicrobial activity under relatively high ionic-strength conditions.HBD-3 can also regulate signaling in dendritic cells, monocytes, and keratinocytes. These effects are strongly dependent on concentration and tissue context.
3.4 HBD-4 and Other β-Defensins
HBD-4 is expressed mainly in epithelial tissues of the respiratory, gastrointestinal, and urogenital tracts and can be upregulated following infectious or inflammatory stimulation.Members such as HBD-5 and DEFB118 exhibit greater tissue selectivity and are mainly associated with local antimicrobial defense in the urogenital tract, protection of the sperm surface, and maintenance of reproductive tract immune homeostasis.
Table 2. Functional comparison of major human defensins
Member | Major Source | Expression or Storage Pattern | Major Functional Mechanisms |
HNP-1–3 | Neutrophils | Pre-stored in azurophilic granules | Membrane activity, intragranular microbial killing, and inflammatory regulation |
HNP-4 | Neutrophils | Stored in granules | Strong activity against certain Gram-negative bacteria |
HD5 | Small-intestinal Paneth cells | Stored in granules and matured by proteolysis | Direct membrane activity and intestinal crypt protection |
HD6 | Small-intestinal Paneth cells | Released from granules | Self-assembly into nanonets that entrap pathogens |
HBD-1 | Multiple mucosal epithelia | Relatively constitutive expression | Basal antimicrobial defense regulated by redox status |
HBD-2 | Skin and mucosal epithelia | Induced by infection and inflammation | Antimicrobial activity and CCR6-associated immune-cell recruitment |
HBD-3 | Skin and mucosal epithelia | Inducible expression | Broad-spectrum antimicrobial and immunoregulatory activity |
HBD-4 | Multiple mucosal epithelia | Induced by infection and inflammation | Mucosal antimicrobial defense and local inflammatory regulation |
DEFB118 | Reproductive tract epithelium | Tissue-selective expression | Local reproductive tract antimicrobial activity and barrier protection |
4 Antimicrobial Mechanisms of Defensins
4.1 Electrostatic Recognition and Accumulation on Microbial Surfaces
Lipopolysaccharides, teichoic acids, and acidic phospholipids on bacterial surfaces generally carry negative charges and can attract positively charged defensins. After defensins accumulate on the microbial surface, their hydrophobic residues approach the lipid bilayer, creating favorable conditions for membrane insertion, peptide aggregation, and lipid rearrangement.The outer leaflet of mammalian cell membranes generally has a lower density of negative charges, providing defensins with a degree of selectivity toward microbial membranes.
4.2 Disruption of Membrane Permeability
Some defensins can insert into microbial membranes and oligomerize, causing thinning of the lipid bilayer, transient membrane defects, or the formation of ion-permeable pores. These changes ultimately lead to membrane-potential dissipation and leakage of intracellular contents.Depending on the defensin and the composition of the microbial membrane, the process may involve pore formation, surface coating, lipid clustering, or nonspecific membrane disruption. Not all defensins should therefore be described uniformly as membrane pore-forming peptides with a fixed pore structure.
4.3 Interference with the Cell Wall and Intracellular Processes
Some defensins bind bacterial cell-wall precursors, lipopolysaccharides, and other membrane-associated molecules, interfering with cell-wall synthesis and outer-membrane stability.
Defensins that enter microbial cells may also affect DNA, RNA, protein synthesis, and enzymatic activity. Their antimicrobial effects are therefore not limited to plasma membrane disruption.
4.4 Pathogen Entrapment and Aggregation
HD6 can form nanonets on pathogen surfaces, while certain other defensins can promote bacterial aggregation. These processes restrict microbial motility, epithelial adhesion, and tissue invasion.
Aggregated microorganisms can be more readily cleared through mucociliary transport, intestinal peristalsis, and phagocytosis by immune cells.
4.5 Antiviral and Antifungal Activity
Defensins can bind viral envelopes, capsids, or host-cell surface molecules and thereby interfere with viral attachment, membrane fusion, and cellular entry.Their antifungal effects may involve plasma membrane damage, cell-wall stress, and disruption of intracellular ion homeostasis. The specific outcome depends on the defensin family member, whether the virus is enveloped, and the composition of the fungal cell wall.
Table 3. Major antimicrobial mechanisms of defensins
Level of Action | Molecular Process | Major Outcome |
Microbial surface recognition | Cationic defensins bind negatively charged membrane components | Accumulation of defensins on pathogen surfaces |
Membrane disruption | Membrane insertion, oligomerization, and lipid rearrangement | Loss of membrane potential and leakage of cellular contents |
Cell-wall interference | Binding to cell-wall precursors or outer-membrane components | Impaired cell-wall synthesis and reduced outer-membrane stability |
Intracellular activity | Effects on nucleic acids, protein synthesis, and enzymatic activity | Inhibition of microbial growth |
Pathogen entrapment | Self-assembly into mesh-like structures or promotion of microbial aggregation | Restricted adhesion and tissue invasion |
Inhibition of viral entry | Binding to viral particles or host-cell surface molecules | Reduced viral attachment, fusion, or cellular entry |
5 Defensin-Mediated Regulation of Immunity and Barrier Function
5.1 Immune-Cell Recruitment
Some β-defensins can promote the migration of immature dendritic cells, memory T cells, and monocytes toward sites of infection through chemokine receptor-associated mechanisms.Defensins function not only as antimicrobial effector molecules but also as signals of epithelial injury and infection, contributing to changes in the local immune-cell composition.
5.2 Regulation of Inflammatory Signaling
Defensins can bind microbial components such as lipopolysaccharides and alter the intensity of their stimulation of pattern-recognition receptors. They may also affect NF-κB, MAPK, and cytokine signaling in epithelial and immune cells.Controlled local defensin release facilitates pathogen clearance, whereas persistent overexpression or extensive extracellular release may amplify inflammation and tissue injury.
5.3 Epithelial Repair and Barrier Integrity
Molecules such as HBD-2 and HBD-3 can affect epithelial cell migration, proliferation, and cytokine release. Defensin expression during the early stages of infection helps restrict pathogen dissemination and supports barrier repair. Persistent abnormal expression may contribute to chronic inflammation, epithelial hyperplasia, and tissue remodeling.
5.4 Regulation of Microbial Community Structure
Defensins in the intestine, skin, and respiratory tract exert selective pressure on different microorganisms, influencing microbiota composition and the spatial relationship between microbes and epithelial surfaces.Abnormal Paneth cell function, granule release, or maturation of HD5 and HD6 may alter the intestinal microbiota and increase the likelihood that pathogens will reach the intestinal crypt region.
6 Defensins in Disease Research
6.1 Infectious Diseases
Bacterial, fungal, and viral infections can all alter defensin expression. Increased HNP levels are generally associated with neutrophil activation and degranulation, whereas elevated HBD-2 and HBD-3 more commonly reflect epithelial inflammatory responses.Increased defensin levels may represent effective host defense but may also accompany severe inflammation and tissue injury.
6.2 Inflammatory Bowel Disease
Abnormalities in Paneth cell function, granule release, autophagy, and endoplasmic reticulum homeostasis can all affect HD5 and HD6. Reduced Paneth cell α-defensins may occur in some forms of ileal Crohn’s disease, but this phenotype is also influenced by NOD2, ATG16L1, the severity of inflammation, and the intestinal microbiota. The disease cannot be attributed simply to the deficiency of a single defensin.
6.3 Skin and Respiratory Diseases
HBD-2 and HBD-3 can be markedly elevated in psoriasis, skin infections, and airway inflammation. The ionic strength, pH, protease activity, DNA content, and mucin content of respiratory mucus can all influence defensin activity. Local antimicrobial capacity may therefore remain insufficient even when defensin concentrations are normal or increased.
6.4 Urogenital Diseases
HBD-1, HBD-2, and other β-defensins participate in the basal defense of the urogenital epithelium. Infection, the hormonal environment, and the state of epithelial differentiation can all alter their expression.Tissue-specific members such as DEFB118 may also contribute to sperm-surface protection and microbial control in the reproductive tract.
6.5 Interpretation of Defensin Detection Results
ELISA primarily measures the concentration of immunoreactive defensins in a sample. It generally cannot directly distinguish precursor peptides from mature peptides, oxidized forms from reduced forms, or monomers from aggregates, nor can it demonstrate that the detected molecules retain antimicrobial activity.Salt concentration, pH, serum proteins, mucus components, and proteolytic degradation can all alter the actual biological effects of defensins.
Table 4. Major factors affecting the interpretation of defensin measurements
Influencing Factor | Possible Change | Key Consideration |
Neutrophil abundance | Increased HNP-1–4 | Distinguish local antimicrobial responses from systemic inflammation |
Induced epithelial expression | Increased HBD-2 and HBD-3 | Interpret together with infection severity and tissue injury |
Proteolytic processing | Altered ratio of precursor to mature peptides | Total protein levels do not represent mature peptide activity |
Redox status | Altered disulfide bonds and peptide conformation | HBD-1 activity may change substantially |
Ionic strength and pH | Altered membrane binding and insertion | Low-salt in vitro assays may overestimate antimicrobial activity |
Mucus, DNA, and serum proteins | Defensin binding or partial inactivation | The concentration of free active peptide may be lower than the total concentration |
Peptide aggregation and self-assembly | Altered membrane activity or trapping capacity | HD6 evaluation should focus on nanonet formation rather than only microbial killing rates |
7 Products for Defensin Research
7.1 Products for Studying Human α-Defensins and HNPs
Catalog # | Product Name | Grade & Purity | Molecular Action and Research Positioning |
Defensins, Alpha, Mixed from Human Neutrophils (HNP, Human Neutrophil Peptides) | ≥95%(SDS-PAGE), Extinction Coefficient: 2.95 | Contains multiple human neutrophil α-defensins that can bind microbial membranes and increase membrane permeability; used to evaluate the overall antimicrobial effects of HNPs | |
Defensin HNP-1 human | — | Cationic α-defensin that binds bacterial membranes and alters membrane permeability; used to investigate the direct antimicrobial activity of HNP-1 | |
Defensin HNP-1 human TFA | ≥98% | TFA salt form of HNP-1 for concentration-gradient, microbial membrane injury, and dose–response studies | |
Defensin HNP-2 human | — | N-terminal processing product associated with HNP-1 and HNP-3; used to compare membrane-binding capacity and antimicrobial spectra among HNP members | |
Defensin HNP 4 | — | Differs in sequence from HNP-1–3 and exhibits strong activity against certain Gram-negative bacteria; used for functional comparison of HNP family members | |
Human α-defensin 5 | — | Paneth cell-derived α-defensin that restricts intestinal pathogens through membrane activity; used to study HD5 antimicrobial activity and intestinal crypt defense | |
Human α-Defensin 6 | — | Self-assembles into fibrous nanonets on pathogen surfaces and restricts microbial adhesion and invasion; used to investigate the pathogen-trapping mechanism of HD6 | |
Recombinant Human DEFa1B Protein | ≥90%(SDS-PAGE) | Recombinant human DEFA1B protein used as an α-defensin antigen, detection reference, and material for protein-binding studies |
7.2 Products for Studying Human β-Defensins
Catalog # | Product Name | Grade & Purity | Molecular Action and Research Positioning |
Human β-defensin-1 | ≥99% | Constitutively expressed β-defensin whose activity is regulated by disulfide bonds and redox status; used to investigate the relationship between HBD-1 conformation and activity | |
Human β-defensin-2 | — | Inflammation-inducible β-defensin with direct antimicrobial and CCR6-associated chemotactic activities; used to study epithelial defense and immune-cell recruitment | |
β-Defensin-4 (human) | — | Human β-defensin 4 peptide that participates in mucosal antimicrobial defense and inflammatory responses; used for HBD-4 functional studies and family-member comparisons | |
Recombinant Human beta-Defensin 1 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, Azide Free, High Performance, PBS Only, ≥98%(SDS-PAGE&HPLC) | High-purity HBD-1 with specified biological activity for antimicrobial assays, dose–response studies, and protein-interaction research | |
Recombinant Human Beta-Defensin 1 Protein | Carrier Free, PBS Only, ≥90%(SDS-PAGE), See COA | Recombinant human HBD-1 protein for antibody detection, protein quantification method development, and molecular interaction studies | |
Recombinant Human Beta-Defensin 3 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, Azide Free, PBS Only, ≥98%(SDS-PAGE&HPLC), 0.5M in TMF | HBD-3 with specified biological activity for broad-spectrum antimicrobial studies, microbial membrane assays, and immune-cell response research | |
beta-defensin 4A | Moligand™ | Human β-defensin 2 (HBD-2) peptide encoded by DEFB4A; it acts as a CCR6 agonist and can be used in HBD-2–CCR6 functional studies | |
Recombinant Human beta Defensin 5 Protein | Carrier Free, PBS Only, ≥95%(SDS-PAGE) | Recombinant human β-defensin 5 protein for antigen detection and molecular comparisons within the β-defensin family | |
Recombinant Human DEFB118 Protein | Carrier Free, His Tag, ≥95%(SDS-PAGE), See COA | Recombinant human DEFB118 protein for detection and molecular interaction studies involving reproductive tract-associated defensins |
7.3 Defensin Antibodies and Genetic Tools
Catalog # | Product Name | Grade & Purity | Molecular Action and Research Positioning |
alpha Defensin 5 Mouse mAb | Carrier Free, ExactAb™, Low Endotoxin, Azide Free, Validated, PBS Only, ≥95%(SDS-PAGE&HPLC), See COA | Specifically recognizes human α-defensin 5 for comparison of HD5 protein levels under different experimental conditions | |
DEFA6 Antibody | ExactAb™, Validated, 1.0 mg/mL | Recognizes DEFA6/HD6 protein for analysis of changes in Paneth cell-derived HD6 expression | |
DEFA1 Human Pre-designed siRNA Set A | — | Downregulates human DEFA1 expression to determine whether HNP-1 release, antimicrobial activity, and inflammatory phenotypes depend on DEFA1 | |
DEFA3 Human Pre-designed siRNA Set A | — | Downregulates human DEFA3 expression to distinguish the contribution of HNP-3 to total HNP levels and associated phenotypes | |
DEFA4 Human Pre-designed siRNA Set A | — | Downregulates human DEFA4 expression to validate HNP-4-associated antimicrobial effects | |
DEFA5 Human Pre-designed siRNA Set A | — | Downregulates human DEFA5 expression to determine whether intestinal antimicrobial and epithelial protective phenotypes depend on HD5 | |
DEFA6 Human Pre-designed siRNA Set A | — | Downregulates human DEFA6 expression to validate pathogen aggregation, restriction of adhesion, and nanonet-associated phenotypes | |
DEFB1 Human Pre-designed siRNA Set A | — | Downregulates human DEFB1 expression to determine whether basal epithelial antimicrobial capacity depends on HBD-1 | |
DEFB103A Human Pre-designed siRNA Set A | — | Downregulates human DEFB103A expression to validate HBD-3-mediated antimicrobial and immunoregulatory effects | |
DEFB4A Human Pre-designed siRNA Set A | — | Downregulates human DEFB4A expression to determine whether inflammation-inducible β-defensin responses depend on DEFB4A | |
DEFB4B Human Pre-designed siRNA Set A | — | Downregulates human DEFB4B expression to distinguish the contributions of DEFB4A and DEFB4B to associated defensin expression | |
Defb3 Mouse Pre-designed siRNA Set A | — | Downregulates mouse Defb3 expression to validate epithelial antimicrobial and mucosal immune phenotypes in mice | |
Defb4 Mouse Pre-designed siRNA Set A | — | Downregulates mouse Defb4 expression to validate infection-induced β-defensin responses |
7.4 Human Defensin Detection Kits
Catalog # | Product Name | Grade & Purity | Molecular Action and Research Positioning |
Human Neutrophil Defensin 1(HNP-1) ELISA Kit | BioReagent | Quantifies immunoreactive HNP-1 in human samples for comparison of HNP-1 levels under conditions involving neutrophil activation or degranulation | |
Human Defensin Alpha 3 (DEFα3) ELISA Kit | BioReagent | Quantifies immunoreactive DEFA3/HNP-3 in human samples to analyze the release of neutrophil α-defensins | |
Human Defensin Beta 1 (DEFβ1) ELISA Kit | BioReagent | Quantifies immunoreactive HBD-1 in human samples to compare basal mucosal defense levels | |
Human Defensin Beta 2 (DEFβ2) ELISA Kit | BioReagent | Quantifies immunoreactive HBD-2 in human samples to compare infection- or inflammation-induced epithelial responses | |
Human Defensin Beta 3 (DEFβ3) ELISA Kit | BioReagent | Quantifies immunoreactive HBD-3 in human samples to compare epithelial antimicrobial and inflammatory states |
7.5 Mouse and Rat Defensin Detection Kits
Catalog # | Product Name | Grade & Purity | Molecular Action and Research Positioning |
Mouse Defensin Alpha 1, Neutrophil (DEFα1) ELISA Kit | BioReagent | Quantifies immunoreactive DEFα1 in mouse samples to compare changes in α-defensin levels | |
Mouse Defensin Alpha 3 (DEFα3) ELISA Kit | BioReagent | Quantifies immunoreactive DEFα3 in mouse samples to analyze α-defensin release | |
Mouse Defensin Alpha 5 (DEFα5) ELISA Kit | BioReagent | Quantifies immunoreactive DEFα5 in mouse samples to compare Paneth cell-associated defensin levels | |
Mouse Defensin Alpha 6 (DEFα6) ELISA Kit | BioReagent | Quantifies immunoreactive DEFα6 in mouse samples to compare intestinal barrier-associated expression | |
Mouse Defensin Beta 1 (DEFβ1) ELISA Kit | BioReagent | Quantifies immunoreactive DEFβ1 in mouse samples to compare basal epithelial defense levels | |
Mouse Defensin Beta 2 (DEFβ2) ELISA Kit | BioReagent | Quantifies immunoreactive DEFβ2 in mouse samples to analyze infection-induced epithelial responses | |
Mouse Defensin Beta 3 (DEFβ3) ELISA Kit | BioReagent | Quantifies immunoreactive DEFβ3 in mouse samples to compare antimicrobial and inflammation-associated expression | |
Mouse Defensin Beta 4 (DEFβ4) ELISA Kit | BioReagent | Quantifies immunoreactive DEFβ4 in mouse samples to compare expression changes under mucosal inflammatory conditions | |
Rat Defensin Beta 1 (DEFβ1) ELISA Kit | BioReagent | Quantifies immunoreactive DEFβ1 in rat samples to compare basal mucosal defense levels |
Defensins establish a multilayered innate defense system through membrane activity, interference with intracellular processes, pathogen entrapment, and immune regulation. α-Defensins are distributed mainly in neutrophils and intestinal Paneth cells, whereas β-defensins primarily maintain epithelial barriers and respond to infectious stimuli. Defensin measurements should be interpreted according to the specific family member, maturation state, redox status, and local microenvironment.
危险品化学品经营许可证(带存储)